Skip to main content
Premium Trial:

Request an Annual Quote

Silence Says Lung Injury Drug Shows Promise in Animal Study


Silence Therapeutics this week announced that it has generated preclinical data showing that its acute lung injury drug Atu111 could boost the survival of mice infected with pneumonia when combined with antibiotics.

Atu111 is comprised of siRNAs against angiopoietin-2, an “antagonistic ligand of Tie-2 signaling ... implicated in progressing endothelial dysfunction in the context of disease pathogenesis for acute lung injury or sepsis,” according to Silence. It is delivered with the firm's proprietary DACC delivery technology, which specifically targets the endothelium.

The preclinical study examined Atu111 with antibiotics in Streptococcus pneumoniae-infected mice, and demonstrated a 90 percent survival benefit for treated animals compared with non-treated ones. Antibiotic treatment alone resulted in a 20 percent survival benefit compared with untreated controls, Silence said.

Silence said it has now begun collaborating with researchers at Hannover Medical School in Germany to further explore the therapeutic effects of Atu111 in animal models of acute lung injury and sepsis.

Earlier this year, Silence CEO Tony Sedgwick told Gene Silencing News that Atu111 is being prepared to enter clinical testing in 2013 (GSN 2/16/2012).

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.